Andere Sprachen Summit Therapeutics Inc.

Aktien

A2QDFS

US86627T1088

SMMT

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 10.04.2026			% 5 Tage	Veränd. 1. Jan.
19,67 ^USD	+1,86 %		+1,50 %	+12,46 %

27.03.	Summit Therapeutics Inc. kündigt Präsentation mehrerer Ivonescimab-Datensätze aus Phase-III-Studien bei fortgeschrittenem NSCLC auf dem ELCC 2026 an	CI
11.03.	Summit Therapeutics Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM

Andere Sprachen

27.03.	Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy
27.03.	Health-Related Quality of Life With Ivonescimab Versus Pembrolizumab for PD-L1 Positive, Non–Small Cell Lung Cancer (HARMONi-2): A Randomised, Double-Blind, Phase 3 Study in China
27.03.	Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026
27.03.	Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
27.02.	Summit Therapeutics to Present at Upcoming Investor Conferences
23.02.	Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise
23.02.	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q4 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.09
23.02.	Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
23.02.	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
17.02.	Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
09.02.	Avacta appoints new chief scientific officer, plans clinical trials
09.02.	Avacta Therapeutics Announces Executive Changes
30.01.	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30.01.	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
29.01.	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
29.01.	Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab
29.01.	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
13.01.	AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says
12.01.	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
12.01.	Summit Therapeutics, GSK Team up on Clinical Trial for Combination Cancer Therapy
12.01.	Summit Therapeutics Files Marketing Application for Lung Cancer Therapy
12.01.	Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
12.01.	Summit Therapeutics Announces Clinical Trial Collaboration with GSK plc to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate
12.01.	Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
10.01.	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)